Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
International Journal of Molecular Sciences|February 28, 2020
Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AMLStephen S Y Lam, Anskar Y H Leung
Biomedical Engineering Online|December 15, 2015
Cell adhesion manipulation through single cell assembly for characterization of initial cell-to-cell interactionXue Gou, Ran Wang, Stephen S Y Lam, et al.
Blood|March 11, 2014
A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AMLCheuk Him Man, Stephen S Y Lam, Murphy K H Sun, et al.
British Journal of Haematology|December 6, 2023
Distinct karyotypic and mutational landscape in trisomy AMLStephen S Y Lam, Sze P Tsui, C Y Fung, et al.
Therapeutic Advances in Hematology|November 17, 2025
Early measurable residual disease detection post-haematopoietic stem cell transplantation in acute myeloid leukaemiaSze P Tsui, Stephen S Y Lam, Chun H Au, et al.
Nature Communications|April 6, 2026
Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trialLi-Chuan Zheng, Kelvin K W Wong, Stephen S Y Lam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2025
Mechanism of Initial Favorable Response to Decitabine in TP53-Mutated MDS/AML and Potential Mechanisms of Subsequent RelapseNelson K L Ng, Stephen S Y Lam, Lichuan Zheng, et al.
Science Translational Medicine|October 7, 2016
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemiaStephen S Y Lam, Eric S K Ho, Bai-Liang He, et al.
Pageof 2